These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25843460)

  • 1. [Tumor lysis syndrome after FOLFIRI+cetuximab for ascending colon cancer].
    Matsuyama S; Kuramoto T; Tanaka R; Hashiguchi K
    Nihon Shokakibyo Gakkai Zasshi; 2015 Apr; 112(4):714-20. PubMed ID: 25843460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ileal perforation following cetuximab and FOLFIRI chemotherapy in a patient with ascending colon cancer with peritoneal carcinomatosis.
    Kim YW
    J BUON; 2017; 22(3):804-805. PubMed ID: 28730797
    [No Abstract]   [Full Text] [Related]  

  • 3. [Management for adverse events associated with FOLFIRI plus cetuximab or panitumumab].
    Masuishi T; Muro K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():587-91. PubMed ID: 25831828
    [No Abstract]   [Full Text] [Related]  

  • 4. [A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
    Toyokawa A; Nakajima T; Inui K; Yamashita H; Gon H; Kanemitsu K; Tanaka K; Tsukamoto T; Hamabe Y; Ishida T
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1167-9. PubMed ID: 19620810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of multiple skin metastases from cancer of the descending colon responding to FOLFIRI/cetuximab therapy].
    Kadota T; Osuga T; Ogawa H; Kitami M; Ishimura M; Shigaki Y; Nakajima E; Nakata S; Kadota C; Hirano S; Ikura Y; Iwai Y; Yoshikawa T; Ueno N; Tamura T
    Nihon Shokakibyo Gakkai Zasshi; 2014 Jan; 111(1):115-23. PubMed ID: 24390266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
    Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Standard chemotherapy for colonic neoplasms].
    Hyodo I
    Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):283-8. PubMed ID: 17370594
    [No Abstract]   [Full Text] [Related]  

  • 8. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V;
    Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
    Hentrich M; Schiel X; Scheidt B; Reitmeier M; Hoffmann U; Lutz L
    Acta Oncol; 2008; 47(1):155-6. PubMed ID: 18097781
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
    Schimanski CC; Staib F; Göhler T; Hebart H; Heike M; Neise M; Rudi J; Geer T; Dingeldein G; Lang C; Ehscheidt P; Flohr T; Josten KM; Karthaus M; Schmittel A; Wierecky J; Boller E; Indorf M; Wörns MA; Galle PR; Moehler M
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1023-1034. PubMed ID: 28197787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.
    Boisdron-Celle M; Metges JP; Capitain O; Adenis A; Raoul JL; Lecomte T; Lam YH; Faroux R; Masliah C; Poirier AL; Berger V; Morel A; Gamelin E
    Semin Oncol; 2017 Feb; 44(1):24-33. PubMed ID: 28395759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A Case of Fatal Interstitial Pneumonia during FOLFIRI plus Cetuximab Therapy for Liver Metastasis of Colon Cancer].
    Aoyagi H; Ito H; Higuchi K; Koseki K; Watanabe I; Tanaka Y; Suzuki K; Nishi N; Nihei Z; Ito M
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):51-53. PubMed ID: 29362307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].
    Ando M; Nagahama T; Fukuda A; Ami K; Kurokawa T; Hataji K; Ganno H; Kawasaki N; Arai K; Okada Y; Tei S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2288-90. PubMed ID: 21224550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan.
    Oztop I; Demirkan B; Yaren A; Tarhan O; Sengul B; Ulukus C; Akin D; Sen M; Yilmaz U; Alakavuklar M
    Tumori; 2004; 90(5):514-6. PubMed ID: 15656341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
    Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
    Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
    Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
    Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
    Goto A; Suzuki K; Hasegawa Y; Sukawa Y; Fujii K; Nishimura S; Yonezawa K; Abe T; Shinomura Y
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):169-71. PubMed ID: 20087056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
    Aroldi F; Zaniboni A
    Recenti Prog Med; 2015 Dec; 106(12):653e-6e. PubMed ID: 26780078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.